Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 10/20 | 0.67 |
| ▸ | PDE4A | P27815 | 2/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800531 | 0.82 | PDE4A (0.52) | ADH5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26614123 | 0.82 | ADH5 (0.54) | ADH5CYP3A4BAZ2BHTTMAPT | |
| SCHEMBL15924858 | 0.82 | ADH5 (0.64) | ADH5CYP3A4BAZ2BDHODHENPP2 | |
| SCHEMBL12316378 | 0.81 | CYP11B1 (0.52) | ADH5CYP3A4BAZ2BHTTMAPT | |
| SCHEMBL17630071 | 0.81 | ADH5 (1.00) | ADH5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26614180 | 0.79 | ADH5 (0.54) | ADH5CYP3A4BAZ2BHTTMAPT | |
| SCHEMBL12117429 | 0.79 | CYP11B1 (0.56) | ADH5CYP3A4BAZ2BMAPTLMNA | |
| SCHEMBL5806043 | 0.78 | CYP11B1 (0.52) | ADH5CYP3A4BAZ2BHTTMAPT | |
| SCHEMBL28815194 | 0.78 | ADH5 (0.62) | ADH5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6948718 | 0.78 | MAP2K1 (0.48) | ADH5PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070161616-A1 | Method for treating glaucoma IIB | SYNVISTA THERAPEUTICS, INC. | 2007-07-12 | — | — | US | disclosed |
| EP-1785134-A2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1359910-A4 | METHOD FOR TREATING GLAUCOMA II B | ALTEON INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| EP-1248615-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020119970-A1 | Method for treating glaucoma IIB | SYNVISTA THERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002053158-A1 | METHOD FOR TREATING GLAUCOMA IB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002053156-A1 | METHOD FOR TREATING GLAUCOMA II B | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002053161-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001052847-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161616-A1 | Method for treating glaucoma IIB | NDUFB9, NDUFB2, NDUFB7 | ADH5 2265/4885PDE4A 981/4885PDE4B 604/4885 |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, NDUFAB1, HSPE1 | ADH5 1235/4885PDE4A 1914/4885PDE4B 2600/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | ADH5 2498/4885PDE4A 435/4885PDE4B 542/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | ADH5 1640/4885PDE4A 1380/4885PDE4B 1421/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | ADH5 1158/4885PDE4A 777/4885PDE4B 872/4885 |
| US-20020119970-A1 | Method for treating glaucoma IIB | NDUFB9, NDUFB2, NDUFB7 | ADH5 2342/4885PDE4A 1414/4885PDE4B 1048/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | ADH5 1563/4885PDE4A 3166/4885PDE4B 3427/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | ADH5 1022/4885PDE4A 736/4885PDE4B 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.